drugset / Trial / NCT02336685

Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001

NCT02336685

Phase 3 Completed 79 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to demonstrate the efficacy, safety, and tolerability of fulranumab as adjunctive therapy compared with placebo in participants with chronic moderate to severe pain and functional impairment from knee or hip osteoarthritis that is not adequately controlled by current pain therapy.

Timeline

Start
2015-07-07
Primary completion
2016-09-16
Completion
2016-09-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Fulranumab Monoclonal antibody 1 mg Subcutaneous
Subject Fulranumab Monoclonal antibody 3 mg Subcutaneous

Indications